August 2012
FDA has cleared for marketing in the U.S. Xenolith’s device for use in procedures involving Intracorporeal Shock Wave Lithotripsy and patients diagnosed with kidney stones.
Download press release by VLSI, one of Xenolith’s investors.
CE Mark
November 2011
Xenolith receives a CE mark for XenX™
ISO Certification
August 2011
Xenolith certified for ISO 13485